• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

“AI enables animal-free predictions of drug toxicity and efficacy”

Rashmi NSH by Rashmi NSH
1 year ago
in Science News
0
drug

Dr.Mukesh Gupta on Balancing Ethics and Innovation in Biomedicine

In a field where the future of human health converges with animal science and regenerative medicine, Dr.Mukesh Kumar Gupta stands as a formidable figure. Currently serving as Director of ICMR-NARFBR in Hyderabad, Dr. Gupta has worked across institutions in India and South Korea, contributing to critical advancements in transgenic animals, preclinical trials, cryopreservation, and biomaterials.Dr. Gupta’s integrative vision—where technology, ethics, and scientific collaboration converge—positions NARFBR as a crucial player in India’s biomedical future. As India aims to become self-reliant in health innovation, leaders like Dr. Gupta provide the scientific and moral compass needed for the journey. In this wide-ranging conversation with Naresh Nunna of Neo Science Hub, he shares insights into the future of translational research, ethical biotechnologies, and India’s preparedness for global health challenges.

Dr Mukesh 5 | Neo Science Hub

I. Reproductive Biotechnology and Transgenic Animals:

Your research has significantly contributed to the field of reproductive biotechnology, particularly focusing on male germline stem cells and transgenic animals. Could you elaborate on the most promising advancements in these areas and their potential implications for human and animal health?

I had started my career with somatic cell nuclear transfer (SCNT), which is a very robust technology for cloning of animals and producing genetically-modified transgenic animals to produce proteins of pharmaceutical importance or to humanize the pigs for xenotransplantation of their solid organs into humans. While in South Korea, our team produced 11 different types of transgenic mice, chicken, pigs, and cattle embryos. We also developed a new patented method called oocyte-mediated gene transfer for transgenesis. Upon return to India, I shifted my focus to male germline stem cells and in vitro spermatogenesis. These testis-derived stem cells have utility in the restoration of male infertility in prepubertal cancer patients undergoing chemotherapy. We developed and optimized an in vitro technique to differentiate these stem cells into spermatozoa in petri plates, which can avoid the re-introduction of metastatic cells upon transplantation. Moreover, it may also be possible in the near future to develop a simple method for transgenic animals using in vitro produced spermatozoa.

What are the major challenges in translating research on male germline stem cells into clinical applications, and how can these challenges be addressed effectively?

Transplantation of male germline stem cells is currently not possible in humans due to ethical and safety concerns. Moreover, research on human male germline stem cells has not been easy. The number of such cells in the testis is very small and hence, difficult to expand in vitro. More research is necessary to standardize the protocol and make it scalable under GMP conditions for clinical applications.

With the increasing focus on genetic engineering and genome editing technologies, how do you see the future of transgenic animal models evolving, and what ethical considerations should be prioritized?

Transgenic animal technologies are quite mature technologies, although the number of transgenic animals reported from India is very limited. Newer genome editing technologies, such as CRISPR-Cas, make transgenic animal production more versatile with traditional technologies, such as pronuclear microinjection or SCNT. We are yet to see the production and usage of new transgenic animals in India for pharmaceutical protein production, xenotransplantation, or agriculture. However, momentum is gaining to produce transgenic mouse models for human diseases. These transgenics, engineered to lack or gain a gene function, are vital for complex disease modelling and understanding human diseases, including the evaluation of drugs and vaccines for efficacy or mechanism of action. The creation of “humanized” animal models, where human genes, cells, or even tissues are integrated into an animal to study human-specific biology or disease mechanisms, will become more advanced. This is particularly valuable for drug testing and understanding human immune responses. One shouldn’t be surprised to even see a human organ (say, a kidney) being produced in transgenic pigs in future.

With the increasing sophistication of animal model creation comes the greater demand for precision, efficiency, and animal ethics. While the former is important to ensure unintended phenotypes or lifelong adverse impacts on transgenic animals’ lives, the latter is built on the “more with less” paradox for the usage of animals. It is very important that the intrinsic value of animals is acknowledged and their dignity and well-being are respected, rather than viewing them merely as tools for research. Furthermore, strict containment protocols will be necessary to prevent the unintended release of transgenic animals into the environment and a potential ecological disruption, particularly for those transgenics whose genetic modification confers a competitive advantage to alter ecosystems (e.g., faster growth, disease susceptibility, etc.).

NARFBR houses a variety of animal models. How do you envision expanding the range of available models to cater to the evolving needs of biomedical research, particularly in emerging areas like gene therapy and regenerative medicine?

The recent COVID-19 pandemic has taught many lessons to mankind. The vaccine made by the Indian Council of Medical Research (ICMR) has saved lives. During its making, our country faced difficulty in obtaining laboratory animals for the pre-clinical trials of the indigenous vaccine, which was mandated as per the Drugs and Cosmetics Rules and other regulatory guidelines worldwide. Today, ICMR-NARFBR houses a range of lab-grown animals that are necessary for the country’s preparedness for any such pandemic in future. The institute also houses a few transgenic animals that are required for regulatory preclinical trials of cell and gene therapy, such as CAR-T. The institute is capable of conducting regulatory preclinical trials for such novel therapies of national importance.

  • IMG20241126095612 1 | Neo Science Hub
  • IMG20240815084752 3 | Neo Science Hub
  • NARFBR 1 | Neo Science Hub
  • IMG 20240815 085101 2 | Neo Science Hub

What are the key factors that influence the successful development and application of transgenic animal models, and how can these factors be optimized to enhance research outcomes?

Production of transgenic animals requires a good team of embryologists, genetic engineers, and trained gynaecologists and obstetricians. One needs to invest in training genetic engineers for expression vector design and advanced editing technologies, which are different from those required for cell culture or bacterial culture systems. Similarly, while there are many embryologists working in human assisted reproductive technology (ART) laboratories, the trained human resources for the micromanipulation of animal embryos are limited. Strategic funding for the development and maintenance of transgenic animal resources and technologies is also vital. One also needs to strengthen regulatory and infrastructural support to understand evolving guidelines and ensure compliance.

II. Preclinical Trials and Drug Development:

Given your expertise in preclinical trials, what are the critical considerations in designing and conducting these studies to ensure their validity and translatability to human clinical trials?

There are several. In case of regulatory drug toxicology studies, the foremost consideration is the careful selection of animal models to mimic the human disease pathophysiologyand drug metabolism. For example, it is a general tendency to choose beagle dogs as a large animal model for drug toxicity studies. However, the correct animal model is the one that shows drug metabolism similar to humans. The experimental design also needs careful consideration of sample sizes, randomization, blinding, and well-defined endpointsto minimize bias and maximize the validity of results. Furthermore, careful consideration of inter-species differences in physiology and drug responseis paramount to bridge the translational gap and an appropriate design of subsequent human trials. On the other hand, for non-regulatory studies and efficacy studies, it is important that researchers consider the use of advanced in vitro and ex vivo assays, such as microphysiological systems, organoids, organ culture, etc., before resorting to animal studies. These technologies have matured exponentially as an alternative to animal models and have proven very useful in reducing animal usage.

How can animal welfare and ethical considerations be effectively integrated into preclinical research, while still ensuring the scientific rigor and reliability of the studies?

Effectively integrating animal welfare with scientific rigor centers on the principles 3Rs: Replacement, Reduction, and Refinement. Replacement prioritizes non-animal alternatives and advanced technologies, such as microphysiological systems, organ-on-a-chip, etc., and New Approach Methodologies (NAMs), such as AI-driven in silico modelling, which can offer human-relevant data and align with regulatory shifts like the FDA’s push to reduce animal testing. Reduction involves optimizing the study designsand employing robust statistical analyses to minimize animal numbers to obtain meaningful data. On the other hand, Refinement focuses on enhancing animal well-being through enriched environments, superior pain management, and positive reinforcement training, recognizing that less-stressed animals yield more reliable scientific outcomes, besides being humane to animals. Adherence to these principles must be ingrained in study personnel and researchers through regular training and robust ethical oversight by committees like IAEC.

What are the latest advancements in preclinical models for specific disease areas, such as cancer, infectious diseases, and neurological disorders, and how are these models contributing to drug discovery and development?

Preclinical animal modelsare undergoing a transformative revolution across various disease areas, particularly after the push from regulators on the use of alternatives to animal models. Advancements like Patient-Derived Xenografts (PDXs) in humanized mice and organoids have become crucial for the preclinical evaluation of cancer therapies, such as CAR-T. CRISPR-Cas9 gene editing is also being increasingly used to create sophisticated genetically-engineered mouse models that can precisely replicate human cancer mutations. For infectious diseases, beyond traditional animal models, cutting-edge organ-on-a-chip systems, such as lung-on-a-chip or gut-on-a-chip, are proving useful as human-relevant infection models for high-throughput drug screening and toxicity assessment of drugs like monoclonal antibodies. Similarly, in neurological disorders, which have historically faced challenges due to the complexity of the brain and the blood-brain barrier, induced pluripotent stem cell (iPSC)-derived neuronal cultures and cerebral organoids are proving invaluable. These models allow for studying disease mechanisms, target identification, and testing novel therapies, including gene therapies and advanced antibody-drug conjugates (ADCs) that can cross the blood-brain barrier. Collectively, these sophisticated preclinical models are leading to more relevant and predictive data, accelerating the identification of promising drug candidates, reducing attrition rates in clinical trials, and ultimately bringing more effective treatments to patients faster.

How can the collaboration between academia, industry, and regulatory bodies be strengthened to accelerate the translation of preclinical findings into effective therapies for human diseases?

There is excellent research going on in several Indian academic and research institutions, including IITs, NITs, CSIR (e.g, CDRI, IICT, IICB, etc.), and DBT (e.g., NIAB, THSTI, etc.). And of course, ICMR is at the forefront. The state universities are also contributing to cutting-edge research in drug development. However, there appears to be a big gap between academic, industry, and regulatory bodies in the therapeutic translation of these discoveries. There is a critical need for dialogue between academic institutions, industries, and regulatory bodies to align academia’s innovative research with industry’s development insights and regulatory bodies’ guidance on compliance and accepted methodologies, especially for emerging New Approach Methodologies (NAMs). Establishing shared platforms and public-private consortia could be one way to foster collaboration and translate pre-clinical findings into effective clinical trials. This integrated approach has been taken up by ICMR, which now provides a MedTech platform for complete handholding of innovators from Proof-of-Concept to Market validation, driven by open communication and shared objectivesfor transforming scientific discoveries into effective treatments. The MedTechmitra is a joint initiative of ICMR with NITI Aayogin partnership with CDSCO, BIS, GeM, and Department of Pharmaceutics to foster development of affordable and accessible indigenous Therapeutics, Vaccines and Medical Devices/ In-Vitro Diagnostics by providing strategic handholding support to MedTech innovators for clinical evaluation, regulatory facilitation and uptake of new products. It can be accessed online through https://medtechmitra.icmr.org.in/ for complete handholding.

What role do you see artificial intelligence and machine learning playing in optimizing preclinical studies and improving the predictive power of animal models for human responses?

AI has already proven useful in big-data analysis for making sense of vast omics and phenotypic datasets to identify subtle patterns for more accurate predictions of drug efficacy and toxicity, and better target identification. ML algorithms have also been used in experimental designs for automating behavioral analysis in animal models to provide objective and reproducible welfare assessments and disease progression insights. AI/ML is increasingly being used as NAMs and is expected to transform preclinical studies by reducing animal usage. For example, AI/MLis being used to analyze metabolic responses and cellular imaging to capture subtle changes in tissue morphology in organ-on-a-chip technology and identify drug-induced toxicity or efficacy patterns far beyond human capacity. This enables high-throughput screening of drug candidates with greater precision and relevance to human physiology. In “in silico” toxicology, trained ML models on extensive chemical structure and toxicity datasets (e.g., from ToxCast or PubChem) are now available to predict potential adverse effects of novel compounds without the need to conduct animal toxicity studies. These computational approacheswould not only accelerate early-stage drug candidate filtering but also would provide mechanistic insights into toxicity pathways. Furthermore, AI can aid in the “e-validation” of NAMs, streamlining the complex process of demonstrating their reliability to regulatory bodies by automating data integration, simulating experiments, and providing robust statistical analysis. All these can help accelerate the acceptance and adoption of these animal-sparing technologies.

III. Biomaterials and Tissue Engineering:

Your work on ROS-responsive materials and nanocomposite scaffolds for bone tissue engineering has shown promising results. Could you discuss the potential clinical applications of these biomaterials and the challenges in their development and implementation?

While at NIT Rourkela, our team, along with collaborators from South Korea, Portugal, and the USA, have worked on several strategies for bone tissue engineering. We have been trying various nanocomposites, including the use of nanohydroxyapatite, carbon nanotubes, monetite-chitosan-gelatin, chitosan-PEO, gelatin-alginate-cerium oxide, gelatin-alginate-graphene oxide, etc. These biomaterials were carefully chosen to improve the mechanical strength, bone architecture, and biocompatibility of the material for bone regeneration and have shown promising results. Among these, a few candidate materials have been very promising and are under pre-clinical trials. Nevertheless, several potential challenges remain in implementing these tissue-engineered constructs for clinical trials. Native bone is a highly complex hierarchical material with high mechanical strength and elastic modulus, which are not easy to recapitulate with biomaterials. This mismatch can lead to issues such as “stress shielding”, poor osteointegration, uncontrolled degradation and poor vascularization upon transplantation. The research is ongoing, and we are still far from clinical trials.

How can the design and fabrication of biomaterials be tailored to specific tissue regeneration needs, and what are the key factors that influence their biocompatibility and efficacy?

That’s a million-dollar question, which scientists are yet to answer. In general, tailoring of biomaterial design for specific tissue regeneration hinges on the correct selection of the biomaterials and their optimized fabrication to scaffolds that mimic the architecture, surface properties, physico-chemical properties and mechanical properties of the target tissue. For instance, in bone tissue engineering, strong osteoconductive ceramics may be preferred, while soft tissues generally benefit from flexible, porous hydrogels. Advanced fabrication techniques like 3D bioprinting enable precise control over scaffold architecture, allowing for the incorporation of biochemical cues like growth factors to actively direct cell behavior and enhance regeneration. In addition, biocompatibility for minimal adverse host response and a degradation rate that aligns with new tissue formation are vital for effective integration and long-term success of the tissue-engineered constructs.

What are the latest advancements in 3D bioprinting and other innovative technologies for tissue engineering, and how are these technologies shaping the future of regenerative medicine?

The latest advancements in 3D bioprinting are primarily on the development of robotic, hand-held bioprinters and novel bioinks that incorporate living cells, growth factors, and even decellularized extracellular matrix to better mimic native tissue environments and promote specific cellular responses. Handheld 3D bioprintersoffer portability and the ability to perform on-demand, in situbioprinting on uneven tissues directly to the patient’s bedside or even to emergency situations.Beyond bioprinting, other innovative technologies, such as Organ-on-a-chip systems, utilizing microfluidics to create miniature functional models of human organs are actively investigated for drug testing and disease modeling. Gene editing technologies, such as CRISPR-Cas9 are also being used for precise modification of cells within bioprinted constructs to correct genetic defects or enhance therapeutic outcomes. An important outcome of the CRISPR-Cas9 in the transformative evaluation of CAR-T cell therapy for cancer. These convergent technologies are expected to shape the future of regenerative medicine by moving beyond simple scaffold creation to the biofabrication of complex, patient-specific tissues and even organs.   

What are the ethical and regulatory considerations surrounding the use of biomaterials and tissue engineering products in clinical settings, and how can these considerations be addressed to ensure patient safety and therapeutic efficacy?

Currently, the clinical availability of tissue-engineered products is limited in the market, and it presents a significant regulatory challenge in evaluating patient safety and therapeutic efficacy. Unlike drugs, tissue-engineered constructs may contain biomaterials, living cells, and loaded growth factors and drugs, each of which has to be evaluated individually or in combination, as the case may be, for pre-clinical safety and biocompatibility before being deemed suitable for pivotal clinical trials. This becomes more challenging if the material is nano-scale, for which the regulatory landscape is different. On the technical front, the physico-chemical and biological evaluation of tissue-engineered products requires heavy capital investments in machinery such as SEM, TEM, XRD, FTIR, etc., besides other tests, which make regulatory studies costly and time-consuming. Besides, the trained and skilled staff for regulatory pre-clinical trials are limited.

How can interdisciplinary collaborations between material scientists, biologists, and clinicians be fostered to accelerate the development and translation of biomaterials for tissue regeneration and repair?

By design itself, tissue engineering is an interdisciplinary field, involving cell biologists, molecular biologists, immunologists, biomaterial scientists, biochemical engineers, metallurgists, mechanical engineers, and experts from electronics, etc., depending on the type of tissue construct or implant that one aims to develop. Thus, consortia of experts and clusters of laboratories that physically or virtually co-locate and provide shared resources and platforms for collaborative projects are quite common. Such labs also collaborate with clinicians right from the earliest stages of biomaterial design to understand the biological complexities and clinical realities to meet the unmet medical needs and patient outcomes. This symbiotic relationship, where each discipline informs and enriches the others, is extremely vital to ensure that biomaterial innovations are not only scientifically sound but also clinically relevant and translatable.

IV. Cryopreservation Techniques:

Your research on cryopreservation techniques, particularly for porcine oocytes, has significant implications for preserving genetic material and improving assisted reproductive technologies. Could you discuss the latest advancements in this field and their potential applications in human fertility preservation and animal breeding programs?

My team has worked extensively in modified Solid Surface Vitrification technology for cryopreservation of living biological materials. Our technology is a very simple technology that requires only an aluminium foil and liquid nitrogen for successful vitrification. Our technology was the first to report successful generation of blastocysts from vitrified oocytes. The modified method was also proven to be successful for cryopreservation of somatic cells, tissues, and even algae. The most recent version of our protocol gives post-warming viability of more than 95% for pig embryos. A latest advancement in the field of cryopreservation is to apply lyophilisation for liquid nitrogen-free storage of cells and tissues. While there are some positive results with cells and spermatozoa, it is still in a developmental stage for its clinical application.

What are the major challenges in cryopreserving different cell types and tissues, and how can these challenges be overcome to improve the viability and functionality of cryopreserved biological materials?

A limitation of our mSSV method is that it requires sterile liquid nitrogen for its application in humans. There are viruses and bacteria that can survive in liquid nitrogen. In order to achieve the highest heat exchange, our method requires direct contact with liquid nitrogen, which may expose it to cross-contamination issues during storage. Another alternative is to use cryogens or slush liquid nitrogen with a higher boiling point.

How can cryopreservation techniques be optimized to minimize cellular damage and ensure the long-term stability and integrity of preserved genetic resources?

This is a tough question, which is yet a puzzle to the scientists. The best probable answer lies in finding and achieving the most suitable cooling rate during cryopreservation. A lot of research is also ongoing to find non-toxic alternatives to the currently used cryoprotectants. Technologies such as directional freezing, microwave-assisted warming, robotic systems for automated cryopreservation, etc., are also actively investigated by various researchers.

What are the ethical and social implications of cryopreservation technologies, particularly in the context of human reproductive medicine and the conservation of endangered species?

There are several interesting ethical and social implications of cryopreserved samples. For example, today it is technically possible to produce a live individual from cryopreserved cells of a dead individual. Scientists have been successful in producing live mice and cattle from the cells of dead animals by using SCNT technology. Theoretically, the same is possible for humans. Posthumous reproduction could bring a lot of ethical and societal issues. Similarly, the ability to use cryopreserved gametes after the death of one partner may raise questions about the definition of parenthood. Who owns the cryopreserved gametes or embryos in cases of separated parents? Cryopreservation of oocytes and embryos also gives an avenue to postpone parenthood while preserving fertility. Widespread elective cryopreservation could contribute to shifts in family formation patterns, potentially increasing the average age of first-time parents and the prevalence of single parenthood or diverse family configurations. If more people delay childbearing, it could exacerbate issues related to an ageing population and the burden on social welfare systems. Nevertheless, cryopreservation has enormous potential to store cells, gametes, and embryos in a frozen state to resurrect the animal species in the event of their extinction.

How do you see the future of cryopreservation evolving, and what role will it play in addressing global challenges related to human health, food security, and biodiversity conservation?

Cryopreservation allows low-cost, long-distance transport of germplasm and, therefore, is very useful for rapid dissemination of elite germplasm from one continent to another. It has also helped in storing the animal germplasm of important transgenic animals until they are required. In humans, the cryopreservation technology has become particularly popular in cord blood banking as an alternative to bone marrow transplantation. The ability to cryopreserve whole organs may prove to be the holy grail, as it would allow long-term preservation of organs for transplantation. I would love to see cryopreserved blood being available in human blood banks in future.

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: featuredsciencenews
Rashmi NSH

Rashmi NSH

Other Posts

Bar chart of decreasing bars beside a line-art antibiotic icon

When the Last Antibiotic Fails: ICMR Finds 91 Per Cent Carbapenem Resistance in a Common Hospital Pathogen

November 21, 2026
0
Map of India's east coast with a stylised cyclone and its forecast track

Akvan Turns North and Drops a Category: IMD Now Expects a Severe Cyclone Between Narsapur and Puri, While Andhra’s Own Forecasters Expect Less

November 21, 2026
0

Antalya’s Last Forty-Eight Hours: Two Contradictory Paragraphs on Fossil Fuels, and India’s Line on the Carbon Budget

Disarm, Don’t Kill: CCMB Scientists Find Two Compounds That Stop a Deadly Fungus Turning Invasive

Eighty Per Cent of the Cost: Andhra Pradesh Raises the Stakes in India’s Chip-Subsidy Contest

Before the First Breath: UNEP and WHO Say Hormone-Disrupting Chemicals Reach Us in the Womb

The Morning Eye Closes: NASA Will Switch Off Terra After 27 Years of Watching the Planet

A Status Lost: Measles Is Endemic Again in the United States, Mexico and Bolivia

Next Post
Cipla

Cipla Reports Strong Quarterly Profits Driven by Domestic Demand

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
11

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist